Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
公司代碼IBO
公司名稱Impact Biomedical Inc
上市日期Sep 16, 2024
CEOHeuszel (Frank D)
員工數量2
證券類型Ordinary Share
年結日Sep 16
公司地址1400 Broadfield Blvd.
城市HOUSTON
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編77084
電話15852321500
網址https://www.impactbiomedinc.com/
公司代碼IBO
上市日期Sep 16, 2024
CEOHeuszel (Frank D)